CohenEE, RosenLS, VokesEE, KiesMS, ForastiereAA, WordenFP, KaneMA, ShermanE, KimS, BycottP, TortoriciM, ShalinskyDR, LiauKF, CohenRB. 2008. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol, 26:4708–4713.
2.
ShermanSI, WirthLJ, DrozJP, HofmannM, BastholtL, MartinsRG, LicitraL, EschenbergMJ, SunYN, JuanT, StepanDE, Schlumberger MJ; Motesanib Thyroid Cancer StudyGroup. 2008. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med, 359:31–42.
3.
KloosR, RingelM, KnoppM, HallN, KingM, StevensR, LiangJ, WakelyPE, VaskoV, SajiM, Rittenberry, ArbogastD, CollamoreM, WrightJJ, GreverM, ShahMH. 2009. Phase II clinical trial of the multi-kinase inhibitor, sorafenib, in metastatic thyroid cancer. J Clin Oncol, 27:1675–1684.
4.
VaishnawAK, GollobJ, Gamba-VitaloC, HutabaratR, SahD, MeyersR, de FougerollesT, MaraganoreJ. 2010. A status report on RNAi therapeutics. Silence, 1:14.
5.
FireA, XuS, MontgomeryMK, KostasSA, DriverSE, MelloCC. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391:806–811.
6.
WangJ, LuZ, WientjesMG, AuJL. 2010. Delivery of siRNA therapeutics: barriers, carriers. AAPS J[Epub ahead of print]
7.
de MartimpreyH, BertrandJR, MalvyC, CouvreurP, VauthierC. 2010. New core-shell nanoparticles for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma. Pharm Res, 27:498–509.
8.
Gilbert-SirieixM, RipocheH, MalvyC, Massaad-MassadeL. 2010. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Thyroid, 20this issue.
